

March 29, 2019

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 8(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir / Madam,

Please take note that the Board of Directors of the Company on Friday, March 29, 2019 approved, modification in following Insider Trading Codes of the Company to make them compliant with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018.

1. Code of practices and procedures for fair disclosures of Unpublished Price Sensitive Information.
2. Code of Conduct to regulate, monitor and report trading by Insiders (including policy for inquiry in case of leak of Unpublished Price Sensitive Information)

The revised codes will be effective from April 1, 2019.


The revised code of practices and procedures for fair disclosures of Unpublished Price Sensitive Information is attached as **Annexure I** to this letter.


We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

For **Dr. Lal PathLabs Limited**


Rajat Kalra
Company Secretary and Legal Head
Encl.: As above



Dr. Lal PathLabs Limited

Corporate Identity Number: L74899DL1995PLC065388
Regd. Office: Block E, Sector - 18, Rohini, New Delhi – 110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Gurugram - 122001
Website: www.lalpathlabs.com
Phone: +91 124 3016500 | Fax: +91 124 4234468

CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURES [under Regulation 8(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015]

1. Introduction

The Securities and Exchange Board of India ("SEBI") notified the SEBI (Prohibition of Insider Trading) Regulations 2015 ("Regulations") on January 15, 2015 and made them effective from May 15, 2015.

The Regulations envisage every Listed Company to formulate a Code of Practices and Procedures for Fair Disclosures of Unpublished Price Sensitive Information ("Code").

In compliance of the above-said regulations and SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 ("Amended Regulations") notified on December 31, 2018, the Board of Directors have approved certain modifications in the existing Code to make it compliant with the Amended Regulations.

This modified Code will become applicable from April 1, 2019.

2. Objective of the Code

The Company endeavors to preserve the confidentiality of Unpublished Price Sensitive Information (UPSI) and to prevent its misuse. To achieve this objective and in compliance with the aforesaid regulations, the Board of Directors have adopted this code.

Dr. Lal PathLabs Limited

The Code ensures timely and adequate disclosure of UPSI which could impact the prices of its securities and maintains the uniformity, transparency and fairness in dealing with all its stakeholders.

3. Definitions

- a. **'Chief Investors Relations Officer' ("CIRO")** means the Compliance Officer & Company Secretary of the Company.
- b. **'Company'** means Dr. Lal PathLabs Limited (hereinafter referred as 'the Company')
- c. **'Compliance Officer'** for the purpose of these regulations means the Company Secretary of the Company.
- d. **"Unpublished price sensitive information" ("UPSI")** means any information, relating to a company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall ordinarily including but not restricted to, information relating to financial results, dividends, change in capital structure, mergers, de-mergers, acquisitions, delisting's, disposals and expansion of business and such other transactions, changes in Key managerial personnel;

The Company will adhere to the following guidelines so as to ensure fair disclosure of events and occurrence(s) that may impact price of its securities:

4. Norms for disclosure of UPSI

- a. **Prompt public disclosure of UPSI**

Dr. Lal PathLabs Limited

UPSI shall be shared by the Company with stock exchanges promptly and shall also be uploaded on the Company's official website (www.lalpathlabs.com), in compliance of regulatory requirements.

b. Uniform and Universal dissemination of UPSI

The disclosure of UPSI shall be on a continuous, immediate, uniform and universal basis.

c. Overseeing and coordinating disclosure(s)

The CIRO shall oversee corporate disclosures and deal with dissemination of information and disclosure of UPSI.

The CIRO shall be responsible for ensuring that the Company complies with continuous disclosure requirements and for overseeing and coordinating disclosure of UPSI to stock exchanges, on the website of the company and to the media.

If any information is accidentally disclosed without prior approval of CIRO the person responsible may inform the CIRO immediately. In such event of inadvertent disclosure of UPSI, the CIRO shall take prompt action to ensure such information is generally available.

In addition to the CIRO, the following persons are also authorized to communicate with the Investors/media:

- i. Chairman
- ii. Managing Director
- iii. Executive Director(s)
- iv. CEO&
- v. CFO

Dr. Lal PathLabs Limited

d. Responding to market rumours

The CISO shall respond to any queries or requests for verification of market rumours by regulatory authorities on behalf of the Company.

The CISO in consultation with the CEO & CFO shall also be responsible for deciding whether a public announcement is necessary for verifying or denying rumours.

The CISO shall also provide appropriate assistance and fair response to the regulatory authorities including the stock exchanges for verification of news reports and market rumours.

5. Process of disseminating information in order to make the UPSI generally available

- Disclosure/dissemination of information may be done through various media so as to achieve maximum reach and quick dissemination.
- The website of the company may provide a means of giving investors a direct access to analyst briefing material, significant background information and questions & answers.

6. Manner of dealing with analyst and research personnel

- (i) *Only Public information to be provided* – A company shall provide only public information to the analyst/research persons/large investors like institutions.
- (ii) *Recording of discussion* - In order to avoid misquoting or misrepresentation, it is desirable that at least two company's representatives be present at meetings with analysts, brokers or institutional investors. The Company shall adopt best practices to make transcripts or records of proceedings of such meetings available on the website of the Company to ensure official confirmation and documentation of disclosures made.

Dr. Lal PathLabs Limited

(iii) *Handling of unanticipated questions* –The Company should be careful when dealing with analysts' questions that raise issues outside the intended scope of discussion. Unanticipated questions may be taken on notice and a considered response given later. If the answer includes UPSI, a public disclosure, if considered appropriate, should be made before responding.

7. UPSI on Need-to-Know basis

UPSI shall be handled on a "need to know" basis i.e. it shall be disclosed only to those where such communication is in furtherance of legitimate purposes, performance of duties or discharge of legal obligations.

8. Policy for Determination of Legitimate Purposes

"Legitimate Purpose" shall include sharing of unpublished price sensitive information in the ordinary course of business by an insider with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants, provided that such sharing has not been carried out to evade or circumvent the prohibitions of these regulations.

Any person in receipt of unpublished price sensitive information pursuant to a "Legitimate Purpose" shall be considered an "insider" for purposes of these regulations and due notice shall be given to such persons to maintain confidentiality of such unpublished price sensitive information in compliance with these regulations.

A structured digital database shall be maintained containing the names of such persons or entities as the case may be with whom information is shared for legitimate purpose along with the Permanent Account Number or any other identifier authorized by law where

Dr. Lal PathLabs Limited

Permanent Account Number is not available. Adequate internal controls and checks such as time stamping and audit trails will also be laid out to ensure non-tampering of such database.

Following factors must be satisfied while determining what constitutes a legitimate purpose

- i. Must be shared in the ordinary of course of business or for Corporate Purpose;
- ii. Required to be done in furtherance of fiduciary duties or in fulfillment of any statutory or contractual obligation;
- iii. The action is executed in a manner which is considered as fair and transparent; and
- iv. Information shared is in the interest of Company and should not result into a personal benefit to the Insider

9. Disclosure of Code on Public Domain

This Code and any amendment thereof shall be published on the Company's website www.lalpathlabs.com

10. Amendments to the Code

The Board of Directors may review or amend this code, in whole or in part, from time to time, as per the requirements of the Companies Act, 2013 or SEBI (Prohibition of Insider Trading) Regulations, 2015 or any other enactments/rules/amendments as may be made applicable.

This Code is in addition to and not in derogation of the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015. In case of any inconsistency, the provisions of the Regulations shall prevail.